326 related articles for article (PubMed ID: 18160515)
1. Fitness of Streptococcus pneumoniae fluoroquinolone-resistant strains with topoisomerase IV recombinant genes.
Balsalobre L; de la Campa AG
Antimicrob Agents Chemother; 2008 Mar; 52(3):822-30. PubMed ID: 18160515
[TBL] [Abstract][Full Text] [Related]
2. Molecular characterisation of the quinolone resistance-determining regions (QRDR) including gyrA, gyrB, parC and parE genes in Streptococcus pneumoniae.
Kakinuma Y; Maeda Y; Mason C; Goldsmith CE; Coulter WA; Matsuda M; Dooley JS; Lowery CJ; Moore JE
Br J Biomed Sci; 2012; 69(3):123-5. PubMed ID: 23057160
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of plasmid-mediated quinolone resistance and mutations in the gyrase and topoisomerase IV genes in Salmonella isolated from 12 tertiary-care hospitals in Korea.
Jeong HS; Kim JA; Shin JH; Chang CL; Jeong J; Cho JH; Kim MN; Kim S; Kim YR; Lee CH; Lee K; Lee MA; Lee WG; Shin JH; Lee JN
Microb Drug Resist; 2011 Dec; 17(4):551-7. PubMed ID: 21830947
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamics of levofloxacin against characterized ciprofloxacin-resistant Streptococcus pneumoniae.
Lister PD
Postgrad Med; 2008 Sep; 120(3 Suppl 1):46-52. PubMed ID: 18931471
[TBL] [Abstract][Full Text] [Related]
5. [Fluoroquinolone resistance determining region mutation in Streptococcus pneumonia isolates].
Zhang FF; Zhao CJ; Wang H
Zhonghua Jie He He Hu Xi Za Zhi; 2013 Dec; 36(12):940-4. PubMed ID: 24503427
[TBL] [Abstract][Full Text] [Related]
6. Infrequent occurrence of single mutations in topoisomerase IV and DNA gyrase genes among US levofloxacin-susceptible clinical isolates of Streptococcus pneumoniae from nine institutions (1999-2003).
Davies TA; Yee YC; Goldschmidt R; Bush K; Sahm DF; Evangelista A
J Antimicrob Chemother; 2006 Mar; 57(3):437-42. PubMed ID: 16431861
[TBL] [Abstract][Full Text] [Related]
7. Rapid screening of fluoroquinolone resistance determinants in Streptococcus pneumoniae by PCR-restriction fragment length polymorphism and single-strand conformational polymorphism.
Ip M; Chau SS; Chi F; Qi A; Lai RW
J Clin Microbiol; 2006 Mar; 44(3):970-5. PubMed ID: 16517885
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of sitafloxacin against clinical strains of Streptococcus pneumoniae with defined amino acid substitutions in QRDRs of gyrase A and topoisomerase IV.
Touyama M; Higa F; Nakasone C; Shinzato T; Akamine M; Haranaga S; Tateyama M; Nakasone I; Yamane N; Fujita J
J Antimicrob Chemother; 2006 Dec; 58(6):1279-82. PubMed ID: 17056610
[TBL] [Abstract][Full Text] [Related]
9. Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.
Rozen DE; McGee L; Levin BR; Klugman KP
Antimicrob Agents Chemother; 2007 Feb; 51(2):412-6. PubMed ID: 17116668
[TBL] [Abstract][Full Text] [Related]
10. Diverse phenotypic and genotypic characterization among clinical Klebsiella pneumoniae and Escherichia coli isolates carrying plasmid-mediated quinolone resistance determinants.
Yang J; Luo Y; Cui S; Wang W; Han L
Microb Drug Resist; 2011 Sep; 17(3):363-7. PubMed ID: 21563956
[TBL] [Abstract][Full Text] [Related]
11. The molecular epidemiology of Streptococcus pneumoniae with quinolone resistance mutations.
Richter SS; Heilmann KP; Beekmann SE; Miller NJ; Rice CL; Doern GV
Clin Infect Dis; 2005 Jan; 40(2):225-35. PubMed ID: 15655739
[TBL] [Abstract][Full Text] [Related]
12. Quinolone resistance mutations in Streptococcus pneumoniae GyrA and ParC proteins: mechanistic insights into quinolone action from enzymatic analysis, intracellular levels, and phenotypes of wild-type and mutant proteins.
Pan XS; Yague G; Fisher LM
Antimicrob Agents Chemother; 2001 Nov; 45(11):3140-7. PubMed ID: 11600369
[TBL] [Abstract][Full Text] [Related]
13. Molecular characterization of clinical Streptococcus pneumoniae isolates with reduced susceptibility to fluoroquinolones emerging in Italy.
Montanari MP; Tili E; Cochetti I; Mingoia M; Manzin A; Varaldo PE
Microb Drug Resist; 2004; 10(3):209-17. PubMed ID: 15383164
[TBL] [Abstract][Full Text] [Related]
14. Novel Ser79Leu and Ser81Ile substitutions in the quinolone resistance-determining regions of ParC topoisomerase IV and GyrA DNA gyrase subunits from recent fluoroquinolone-resistant Streptococcus pneumoniae clinical isolates.
Korzheva N; Davies TA; Goldschmidt R
Antimicrob Agents Chemother; 2005 Jun; 49(6):2479-86. PubMed ID: 15917550
[TBL] [Abstract][Full Text] [Related]
15. [Fluoroquinolone resistance mutations in topoisomerase genes of Salmonella typhimurium isolates].
Guo Y; Pei X; Liu X
Wei Sheng Yan Jiu; 2004 Sep; 33(5):591-4. PubMed ID: 15612489
[TBL] [Abstract][Full Text] [Related]
16. Fluoroquinolone resistance in atypical pneumococci and oral streptococci: evidence of horizontal gene transfer of fluoroquinolone resistance determinants from Streptococcus pneumoniae.
Ip M; Chau SS; Chi F; Tang J; Chan PK
Antimicrob Agents Chemother; 2007 Aug; 51(8):2690-700. PubMed ID: 17548487
[TBL] [Abstract][Full Text] [Related]
17. Accumulation of mutations in DNA gyrase and topoisomerase IV genes contributes to fluoroquinolone resistance in Vibrio cholerae O139 strains.
Zhou Y; Yu L; Li J; Zhang L; Tong Y; Kan B
Int J Antimicrob Agents; 2013 Jul; 42(1):72-5. PubMed ID: 23643392
[TBL] [Abstract][Full Text] [Related]
18. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.
Smith HJ; Walters M; Hisanaga T; Zhanel GG; Hoban DJ
Antimicrob Agents Chemother; 2004 Oct; 48(10):3954-8. PubMed ID: 15388458
[TBL] [Abstract][Full Text] [Related]
19. Contribution of mutations in DNA gyrase and topoisomerase IV genes to ciprofloxacin resistance in Escherichia coli clinical isolates.
Bansal S; Tandon V
Int J Antimicrob Agents; 2011 Mar; 37(3):253-5. PubMed ID: 21236644
[TBL] [Abstract][Full Text] [Related]
20. Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci.
Jorgensen JH; Weigel LM; Ferraro MJ; Swenson JM; Tenover FC
Antimicrob Agents Chemother; 1999 Feb; 43(2):329-34. PubMed ID: 9925527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
